The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 19 December 2007, www.theannals.com, DOI 10.1345/aph.1K157.
The Annals of Pharmacotherapy: Vol. 42, No. 1, pp. 62-70. DOI 10.1345/aph.1K157
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nichol, M. B
Right arrow Articles by O'Connor, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nichol, M. B
Right arrow Articles by O'Connor, R.

ANTICOAGULATION

Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care

Michael B Nichol, PhD

Professor, Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA

Tara K Knight, PhD

Research Associate, Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, University of Southern California

Tom Dow, MS

Data Analyst, Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, University of Southern California

Gail Wygant, RN MS

Director-Cardiovascular, Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE

Gerald Borok, PhD

Director, Health Economics and Outcomes Research, AstraZeneca

Ole Hauch, MD

Director, Health Economics and Outcomes Research, AstraZeneca

Richard O'Connor, MD

Medical Director, Department of Quality Management, Sharp Rees-Stealy Medical Group, San Diego, CA

Reprints: Dr. Nichol, Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA 90033, fax 323/442-1462, mnichol{at}usc.edu

BACKGROUND: Prior research suggests that receiving specialized anticoagulation services enables patients to achieve better clinical outcomes.

OBJECTIVE: To assess the quality of anticoagulation therapy in patients with atrial fibrillation who were enrolled in an anticoagulation clinic (ACC) versus usual care (UC).

METHODS: Using Sharp Rees-Stealy physician group claims data, we estimated time spent in therapeutic range and time to first major bleeding episode or stroke for ACC and UC patients. t-Tests were used to compare time in therapeutic range proportions, and Kaplan-Meier survival analysis was performed to compare rates of bleeding and stroke between groups.

RESULTS: We identified 1107 patients (351 ACC, 756 UC) treated with anticoagulation therapy for atrial fibrillation with more than one international normalized ratio (INR) reported between March 2001 and March 2004. ACC patients spent a greater proportion (68.14%) of time in therapeutic range compared with UC patients (42.07%; p < 0.001). There was a significant difference between groups in average time between INR tests (ACC = 14.31 days, UC = 18.39 days; p < 0.001). ACC patients were 59% less likely to experience a bleed following the index date than were UC patients (HR = 0.41; 95% CI 0.2444 to 0.6999; p = 0.001), but type of care was not a significant predictor for stroke (HR = 0.95; 95% CI 0.5125 to 1.7777; p value NS).

CONCLUSIONS: Results from this observational study reinforce the positive impact that anticoagulation services have on anticoagulation therapy outcomes, emphasizing the importance of providing such services for patients undergoing treatment with warfarin.

Key Words: anticoagulation services, atrial fibrillation, quality of care

Published Online, December 19, 2007. www.theannals.com, DOI 10.1345/aph.1K157


This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
D. A. Cios, W. L. Baker, S. D. Sander, O. J. Phung, and C. I. Coleman
Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis
Am. J. Health Syst. Pharm., May 15, 2009; 66(10): 916 - 925.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc Qual OutcomesHome page
Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell, P. Glasziou, C. Bankhead, and Y. Xu
Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review
Circ Cardiovasc Qual Outcomes, November 1, 2008; 1(2): 84 - 91.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.